A comparative study of lanthanum carbonate and calcium acetate for the treatment of hyperphosphatemia in maintenance dialysis patients
1.Department of Nephrology, the Second Affiliated Hospital of Wenzhou Medical University, Whenzhou, 325027; 2.Department of Paediatric Nephrology, the Second Affiliated Hospital & Yuying Children’s Hospital of Wenzhou Medical University, Whenzhou, 325027; 3.Department of Nephrology, Ningbo NO.2 Hospital, Ningbo, 315010; 4.Department of Nephrology, Ningbo Medical Treatment Center Lihuili Hospital, Ningbo, 315040; 5.Renal Division, Department of Medicine, Emory University School of Medicine, Atlanta, 30322
SHAO Ningjun1,WANG Dexuan2,ZHUANG Jieqiu2, et al. A comparative study of lanthanum carbonate and calcium acetate for the treatment of hyperphosphatemia in maintenance dialysis patients[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(7): 484-.
Abstract：Objective: To explore the efficacy and the effects on vascular calcification between the new type phosphate binder lanthanum carbonate and traditional phosphate binder calcium acetate for hyperphosphatemia in patients undergoing maintenance dialysis. Methods: 80 eligible patients were randomly divided into lanthanum carbonate group and calcium acetate group according to random number table. X-ray measurement was used to evaluate the degree of vascular calcification. Serum phosphorus, calcium, calcium-phosphorus product, and PTH were detected to compare the short-term and long-term efficacy and effects on vascular calcification between the two groups. Results: Serum phosphorus of both two groups were decreased in the short term. In the first two weeks of treatment, serum phosphorus and calcium-phosphorus product between two groups were no significant difference. Treatment for 4 weeks, the levels of lanthanum carbonate group serum phosphorus were decreased significantly compared with the calcium acetate group (P<0.01) and the levels of calcium-phosphorus product were also reduced obviously (P<0.01). After 1 year maintenance treatment, the levels of serum phosphorus and PTH had no obvious difference, both of the two medicine can decrease the levels of serum phosphorus efficiently. However, the calcium-phosphorus product in lanthanum carbonate group was much lower than in calcium acetate group (P<0.01); Serum phosphorus of peritoneal dialysis patients in lanthanum carbonate group was decreased more obvious than hemodialysis patients (P<0.05). Compared the vascular calcification, 12 cases of the lanthanum carbonate group appeared slight calcification, moderately severe calcification 3 case, hypercalcemia 0 case, the rate of adverse effects was 37.5%; 14 cases of calcium acetate group appeared mild vascular calcification, moderately severe vascular calcification in 8 cases, 8 hypercalcemia, the rate of adverse effects was 75.0%. The difference was statistically significant by x2 test (P<0.01). Conclusion: Lanthanum carbonate is effective in the treatment of hyperphosphatemia of dialysis patients with better short-term efficacy, fewer hypercalcemia and lower calcium-phosphorus product compared to calcium acetate. And it has little influence on vascular calcification.
[1] Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J]. J Am Soc Nephro, 2004, 15(8): 2208-2218.
[2] Pasternak RC, Criqui MH, Benjamin EJ, et al. Atherosclerotic Vascular Disease Conference: Writing Group I: epidemiology[J]. Circulation, 2004, 109(21): 2605-2612.
[3] 郭王, 王质刚. 醋酸钙与碳酸钙改善血透患者钙磷代谢的对比研究[J]. 肾脏病与透析肾移植杂志, 1999, 8(1): 31-33.
[4] 高玉春, 李孜, 唐晓红. 碳酸镧治疗维持性血液透析患者高磷血症有效性和安全性的系统评价[J]. 中国循证医学杂志, 2006, 6(10): 727-731.
[5] Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs [J]. Kidney Int, 2006, 70(10): 1858-1865.
[6] Adragao T, Pires A, Lucas C, et al. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients[J]. Nephrol Dial Transplant, 2004, 19(6): 1480-1488.
[7] Adeney KL, Siscovick DS, Ix JH, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD[J]. J Am Soc Nephrol, 2009, 20(2): 381-387.
[8] Shantouf RS, Budoff MJ, Ahmadi N, et al. Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients[J]. Am J Nephrol, 2010, 31(5): 419-425.
[9] KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)[J]. Kidney Int Supp, 2009, (113): S1-130.
[10] 陈楠, 史浩. 慢性肾脏病高磷血症治疗——新型磷结合剂碳酸镧研究进展[J]. 中华内科杂志, 2012, 51(9): 742-744.
[11] Hutchison AJ. Improving phosphate-binder therapy as a way forward[J]. Nephrol Dial Transplant, 2004, 19 Suppl 1: i19-24.
[12] Toussaint ND, Lau KK, Polkinghorne KR, et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial[J]. Nephrology (Carlton), 2011, 16(3): 290-298.
[13] 张晓娟, 郭华, 唐少文, 等. 碳酸镧与传统磷结合剂治疗维持性血液透析患者高磷血症的Meta分析[J]. 中华肾脏病杂志, 2013, 29(5): 339-346.
